Vericel Corporation — Fiscal 2022 Form 10-K Summary
Business context and reporting period
Vericel is a commercial-stage biopharmaceutical company focused on advanced therapies for sports medicine and severe burn care. The filing covers the fiscal year ended December 31, 2022; it is an annual report rather than a quarterly filing. Products included MACI for knee cartilage defects, Epicel for severe burns, and NexoBrid for eschar removal in adults with deep partial-thickness or full-thickness thermal burns.
Financial performance and liquidity
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Total revenue | $164.4 million | $156.2 million | 5.2% |
| MACI revenue | $132.0 million | $111.6 million | 18.3% |
| Epicel revenue | $31.7 million | $41.5 million | (23.6%) |
| NexoBrid revenue | $0.7 million | $3.1 million | (78.5%) |
| Gross profit | $109.8 million | $106.0 million | 3.5% |
| Gross margin | 66.8% | 67.9% | Down 1.1 percentage points |
| Operating loss | $17.1 million | $7.9 million | Loss increased $9.2 million |
| Net loss | $16.7 million | $7.5 million | Loss increased $9.2 million |
| Net loss per share | $0.35 | $0.16 | Loss increased |
| Operating cash flow | $17.7 million | $29.0 million | Down $11.4 million |
Operating expenses were $126.8 million, including $19.9 million of research and development and $106.9 million of selling, general and administrative expense. Non-cash stock-based compensation was $37.2 million, up from $34.3 million. The operating margin was approximately negative 10.4%, compared with negative 5.0% in 2021, and the net margin was approximately negative 10.2%.
At December 31, 2022, Vericel held $51.1 million of cash and cash equivalents and $88.4 million of investments, for total cash, cash equivalents and investments of approximately $139.5 million. Accounts receivable were $46.5 million and inventory was $16.0 million. The company had no outstanding borrowings under its $150.0 million five-year senior secured revolving credit facility, although approximately $6.2 million of the facility was used for letters of credit. Management stated that existing liquidity, product sales and available borrowing capacity should support current operations for at least 12 months following issuance of the financial statements.
Total assets were $273.0 million and shareholders’ equity was $192.3 million. The accumulated deficit was approximately $400.0 million. Operating and finance lease obligations totaled $61.1 million, excluding approximately $98.9 million of future minimum payments under the not-yet-commenced Burlington facility lease.
Material changes versus the prior comparable period
- MACI revenue increased $20.4 million, driven by volume and price growth.
- Epicel revenue declined $9.8 million, primarily due to lower severe-burn incidence and volume.
- NexoBrid revenue declined $2.4 million because BARDA procurement activity completed during the third quarter of 2022.
- Gross profit increased, but gross margin declined because of lower Epicel labor utilization, higher raw-material prices, and increased external storage and manufacturing-facility costs.
- Research and development expense increased 22.4%, partly due to arthroscopic MACI instrument development, increased headcount and higher stock-based compensation.
- Selling, general and administrative expense increased 9.5%, reflecting higher marketing, travel, in-person events, depreciation and stock-based compensation.
- Operating cash flow declined as the net loss increased and working capital absorbed cash, including higher accounts receivable and inventory.
- Investing cash outflows increased to $36.2 million, including $69.6 million of investment purchases and $7.6 million of property and equipment purchases.
Guidance, outlook, risks and unusual items
- The FDA approved NexoBrid on December 28, 2022. Vericel expected U.S. commercial sales to begin in the second quarter of 2023, and MediWound transferred the BLA to Vericel effective February 20, 2023.
- Management is pursuing potential arthroscopic delivery of MACI and anticipated a potential commercial launch in 2024, subject to regulatory and development requirements. The company is also evaluating MACI for ankle cartilage defects.
- Vericel recorded a $7.5 million NexoBrid regulatory milestone as an intangible asset in 2022; the payment was made in February 2023. The license agreement also provides for up to $125.0 million of contingent sales milestone payments and tiered royalties on North American net sales.
- NexoBrid commercialization depends on physician and burn-center adoption, reimbursement, regulatory compliance and MediWound’s ability to manufacture and supply the product. Bromelain supplies originate in Taiwan and manufacturing occurs primarily in Israel, creating geopolitical and supply-chain exposure.
- MACI revenue is seasonal, with historical average sales volumes weighted toward the fourth quarter. Epicel revenue is inherently volatile because severe burns occur sporadically.
- Key risks include continued operating losses, the ability to achieve profitability, reimbursement and collection estimates for MACI, reliance on a single U.S. manufacturing facility, sole-source suppliers including Matricel for the MACI membrane, regulatory compliance, competition, cybersecurity, inflation, geopolitical tensions and possible COVID-19-related disruptions.
- The company reported no material ongoing litigation or material regulatory proceedings. Management and the independent auditor concluded that internal control over financial reporting was effective as of December 31, 2022.
Important facts for investors to verify
- Validate the pace, pricing, gross margin and reimbursement quality of MACI growth, including the $6.1 million MACI contractual allowance.
- Track NexoBrid launch timing, supply availability, adoption, reimbursement, royalties and milestone obligations.
- Assess whether Epicel revenue recovers from the 2022 decline and how severe-burn incidence affects quarterly results.
- Review cash burn, facility construction and lease commitments, including the Burlington facility’s approximately $98.9 million undiscounted lease obligation.
- Monitor progress and regulatory outcomes for arthroscopic MACI and the potential ankle indication.
- Evaluate reliance on MediWound, Taiwan-sourced bromelain, Israel-based manufacturing and single-source suppliers.
- Confirm the company’s ability to reach sustained profitability without equity issuance or debt borrowing.